Literature DB >> 10382899

Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus.

M Kantzanou1, P T Tassios, A Tseleni-Kotsovili, N J Legakis, A C Vatopoulos.   

Abstract

The MICs of vancomycin for 56 random nosocomial Staphylococcus aureus isolates homogeneously resistant to methicillin (homMRSA), 16 heterogeneously resistant isolates (hetMRSA) and 25 susceptible isolates (MSSA) were determined by a standard broth microdilution method. Representative isolates were also tested by an agar incorporation method, the Etest and population analysis. Although always in the susceptible range, MICs of vancomycin for homMRSA were significantly higher than those for hetMRSA or MSSA. Moreover, a homMRSA strain belonging to one of the major Greek MRSA clones contained a sub-population of cells that could grow in the presence of vancomycin 8 mg/L at a frequency of 6.7 x 10(-8).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10382899     DOI: 10.1093/jac/43.5.729

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis.

Authors:  E B Hume; J J Dajcs; J M Moreau; R J O'Callaghan
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  Two international methicillin-resistant Staphylococcus aureus clones endemic in a university hospital in Patras, Greece.

Authors:  M Aires de Sousa; C Bartzavali; I Spiliopoulou; I Santos Sanches; M I Crisóstomo; H de Lencastre
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

Review 3.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 4.  Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.

Authors:  Sebastiaan J van Hal; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

5.  First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand.

Authors:  S Trakulsomboon; S Danchaivijitr; Y Rongrungruang; C Dhiraputra; W Susaemgrat; T Ito; K Hiramatsu
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

6.  Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.

Authors:  Natalia Revilla; Ana Martín-Suárez; Marta Paz Pérez; Félix Martín González; María Del Mar Fernández de Gatta
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

7.  Human leukocytes adhere to, penetrate, and respond to Staphylococcus aureus biofilms.

Authors:  Jeff G Leid; Mark E Shirtliff; J W Costerton; Paul Stoodley
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

8.  Methicillin and Vancomycin Resistant S. aureus in Hospitalized Patients.

Authors:  Poonam Sood Loomba; Juhi Taneja; Bibhabati Mishra
Journal:  J Glob Infect Dis       Date:  2010-09

9.  Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.

Authors:  Maria del Mar Fernández de Gatta; Dolores Santos Buelga; Amparo Sánchez Navarro; Alfonso Dominguez-Gil; Maria Jose García
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 10.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.